New Jersey Commercial Real Estate Investors Bet on Life Sciences Space

Commercial real estate investors across New Jersey are increasingly converting vacant office buildings into life sciences laboratory space, betting that continued pharmaceutical and biotech industry demand will outlast the broader office market's ongoing struggles with elevated vacancy rates.

The conversions typically require substantial capital investment, including upgraded ventilation systems, reinforced flooring, and specialized utility infrastructure necessary for wet lab research space. Despite the higher upfront cost compared to standard office renovation, investors say demand from life sciences tenants has remained resilient even as broader office leasing has softened.

"Traditional office tenants are still cutting their footprint as hybrid work sticks around, but life sciences companies need physical lab space no matter what — you can't run an experiment over video call," said a commercial real estate investor active in several conversion projects. "That distinction is exactly why we're deploying capital into this asset type right now instead of standard office."

New Jersey's decades-long concentration of pharmaceutical company operations has made the state a natural target for these conversions, with investors citing proximity to an established life sciences workforce as a key advantage over other regions attempting similar office-to-lab conversions. Several conversion projects are concentrated along the Route 1 corridor near Princeton, historically one of the state's densest pharmaceutical employment clusters.

Real estate analysts caution that life sciences lab demand, while currently strong, is not immune to industry-wide funding cycles that have periodically slowed biotech company growth in the past.